Picture of Telix Pharmaceuticals logo

TLX Telix Pharmaceuticals Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareAdventurousMid CapMomentum Trap

Momentum

Relative Strength (%)
1m+0.45%
3m+18.47%
6m+78.03%
1yr+14.1%
Volume Change (%)
10d/3m-44.79%
Price vs... (%)
52w High-16.1%
50d MA+15.15%
200d MA+34.19%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)274.24
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value21.96
Price to Tang. Book48.5
Price to Free Cashflown/a
Price to Sales80.56
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-66.52%
Return on Equity-155.07%
Operating Margin-392.2%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Telix Pharmaceuticals EPS forecast chart

Profile Summary

Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The radioactive payload can either be diagnostic (for imaging) or therapeutic, or both. Its lead programs include TLX591-CDx (Illuccix) / TLX591 for diagnosis and treatment of metastatic castrate-resistant prostate cancer, TLX250-CDx/TLX250 for diagnosis and treatment of renal (kidney) cancer, TLX101-CDx / TLX101 for diagnosis and treatment of glioblastoma (brain cancer), and TLX66-CDx (Scintimun) / TLX66 for the treatment of bone marrow conditioning and rare diseases.

Directors

Last Annual
December 31st, 2021
Last Interim
June 30th, 2022
Incorporated
January 3rd, 2017
Public Since
November 15th, 2017
No. of Shareholders
7,021
No. of Employees
158
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
312,816,341

TLX Share Price Performance

Upcoming Events for TLX

Full Year 2022 Telix Pharmaceuticals Ltd Earnings Release

Telix Pharmaceuticals Ltd Annual Shareholders Meeting

Similar to TLX

Picture of Actinogen Medical logo

Actinogen Medical

au flag iconAustralian Stock Exchange - SEATS

Picture of Adalta logo

Adalta

au flag iconAustralian Stock Exchange - SEATS

Picture of Alterity Therapeutics logo

Alterity Therapeutics

au flag iconAustralian Stock Exchange - SEATS

Picture of Amplia Therapeutics logo

Amplia Therapeutics

au flag iconAustralian Stock Exchange - SEATS

Picture of Anatara Lifesciences logo

Anatara Lifesciences

au flag iconAustralian Stock Exchange - SEATS

FAQ

Or unlock with your email

Or unlock with your email